Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in chronic arthritis patients

Journal of Public Health

Volumn 32, Issue 4, 2010, Pages 547-554

  Brach, Mirjam ^a   Sabariego, Carla ^b,c   Herschbach, Peter ^d   Berg, Petra ^d   Engst Hastreiter, Ursula ^b   Stucki, Gerold ^a,b,c,e  

^a SWISS PARAPLEGIC RESEARCH   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

^c ICF Research Branch of WHO FIC CC (DIMDI) at SPF   (Switzerland)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF LUCERNE   (Switzerland)

Author keywords

cognitive behavior therapy; cost effectiveness; economics; health resource; rheumatoid arthritis

Indexed keywords

ADULT; ARTICLE; CHRONIC DISEASE; COGNITIVE THERAPY; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; FEAR; FEMALE; GERMANY; HEALTH SERVICE; HUMAN; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RHEUMATOID ARTHRITIS; UTILIZATION REVIEW;

ADULT; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEAR; FEMALE; GERMANY; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED;

EID: 78649613266     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdq022     Document Type: Article

References (34)

1. Sinclair VG, Wallston KA, Dwyer KA et al. Effects of a cognitivebehavioral intervention for women with rheumatoid arthritis. Res Nurs Health 1998;21(4):315-26.
2. Patten SB, Williams JV, Wang J. Mental disorders in a population sample with musculoskeletal disorders. BMC Musculoskelet Disord 2006;7:37.
3. Lowe B, Willand L, Eich W et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosom Med 2004;66(3):395-402.
4. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008;25(1):72-90.
5. Andlin-Sobocki P, Wittchen HU. Cost of anxiety disorders in Europe. Eur J Neurol 2005;12(Suppl. 1):39-44.
6. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16(4):162-71.
7. Merkesdal S, Ruof J, Schoffski O et al. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44(3):528-34.
8. Myhr G, Payne K. Cost-effectiveness of cognitive-behavioural therapy for mental disorders: implications for public health care funding policy in Canada. Can J Psychiatry 2006;51(10):662-70.
9. Heuzenroeder L, Donnelly M, Haby MM et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry 2004;38(8):602-12.
10. Sharpe L, Allard S, Sensky T. Five-year followup of a cognitivebehavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum 2008;59(3):311-6.
11. Herschbach P, Berg P, Waadt S et al. Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis or cancer. Psychother Psychosom 79(1):31-8.
12. Herschbach P, Berg P, Dankert A et al. Fear of progression in chronic diseases-psychometric properties of the Fear of Progression Questionnaire. J Psychosom Res 2005;58(6):505-11.
13. Burchert H, Hansmeier T, Hessel F et al. DRV-Schriften Band 16 Förderschwerpunkt 'Rehabilitationswissenschaften'-Ökonomische Evaluation in der Rehabilitation. Teil 2: Bewertung der Ressourcenverbrä uche, Vol. 16. Frankfurt am Main: Verband Deutscher Renteversicherungsträ ger, 1999.
14. Hessel F, Kohlmann T, Krauth C et al. DRV-Schriften Band 16 Förderschwerpunkt 'Rehabilitationswissenschaften' - Ökonomische Evaluation in der Rehabilitation. Teil 1: Prinzipien und Empfehlungen für die Leistungserfassung. Vol. 16. Frankfurt am Main: Verband Deutscher Renteversicherungsträger, 1999.
15. Krauth C, Hessel F, Hansmeier T et al. [Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation]. Gesundheitswesen 2005;67(10):736-46.
16. Mehnert A, Herschbach P, Berg P et al. [Fear of progression in breast cancer patients-validation of the short form of the Fear of Progression Questionnaire (FoP-Q-SF)]. Z Psychosom Med Psychother 2006;52(3):274-88.
17. Gandek B, Ware JE, Aaronson NK et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51(11):1171-8.
18. Rote-Liste. Rote Liste Service GmbH. ECV Verlag, 2004.
19. AOK. Vergütungsliste für Orthopädische Hilfsmittel der Primärkassen in Bayern, 2004.
20. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19(23):3219-36.
21. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19(9):1141-64.
22. Drummond MF, O'Brien B, Stoddart GL et al. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. New York: Oxford Medical Publications, 1997.
23. Briggs AH. Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol 2004;16(6):551-61.
24. Herschbach P, Berg P, Waadt S et al. Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis and cancer. Psychother Psychosom, 2010;79(1):31-8.
25. Solomon DH, Warsi A, Brown-Stevenson T et al. Does selfmanagement education benefit all populations with arthritis? A randomized controlled trial in a primary care physician network. J Rheumatol 2002;29(2):362-8.
26. Schweikert B, Jacobi E, Seitz R et al. Effectiveness and costeffectiveness of adding a cognitive behavioral treatment to the rehabilitation of chronic low back pain. J Rheumatol 2006;33(12):2519-26.
27. Goossens ME, Rutten-Van Molken MP, Kole-Snijders AM et al. Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. Health Econ 1998;7(1):39-51.
28. Plant PK, Owen JL, Parrott S et al. Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial. BMJ 2003;326(7396):956.
29. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998;7(8):723-40.
30. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004;13(5):405-15.
31. Chiles JA, Lambert, Michael J et al. The Impact of psychological interventions on medical cost offset: a meta-analytic review. Clin Psychol Sci Pract 1999;6(N2): 204-20.
32. Knapp M, Thorgrimsen L, Patel A et al. Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. Br J Psychiatry 2006;188:574-80. (Pubitemid 43844106)
33. Briggs A. Economic evaluation and clinical trials: size matters. BMJ 2000;321(7273):1362-3.
34. Chuang LH, Kind P. Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. Pharmacoeconomics 2009;27(6):491-505.